University of Liege (ULg), Department of Pharmacy, CIRM, Laboratory of Analytical Chemistry, CHU, B36, 4000 Liege, Belgium.
Arlenda S.A., Avenue de l'Hopital, 1, B-4000 Liege, Belgium.
Anal Chim Acta. 2014 Mar 25;818:7-14. doi: 10.1016/j.aca.2014.02.014. Epub 2014 Feb 12.
During galenic formulation development, homogeneity of distribution is a critical parameter to check since it may influence activity and safety of the drug. Raman hyperspectral imaging is a technique of choice for assessing the distributional homogeneity of compounds of interest. Indeed, the combination of both spectroscopic and spatial information provides a detailed knowledge of chemical composition and component distribution. Actually, most authors assess homogeneity using parameters of the histogram of intensities (e.g. mean, skewness and kurtosis). However, this approach does not take into account spatial information and loses the main advantage of imaging. To overcome this limitation, we propose a new criterion: Distributional Homogeneity Index (DHI). DHI has been tested on simulated maps and formulation development samples. The distribution maps of the samples were obtained without validated calibration model since different formulations were under investigation. The results obtained showed a linear relationship between content uniformity values and DHI values of distribution maps. Therefore, DHI methodology appears to be a suitable tool for the analysis of homogeneity of distribution maps even without calibration during formulation development.
在药物制剂开发过程中,分布均一性是需要检查的关键参数,因为它可能会影响药物的活性和安全性。拉曼高光谱成像是评估感兴趣化合物分布均一性的首选技术。实际上,光谱和空间信息的结合提供了对化学成分和成分分布的详细了解。实际上,大多数作者使用强度直方图的参数(例如均值、偏度和峰度)来评估均一性。然而,这种方法没有考虑空间信息,也失去了成像的主要优势。为了克服这一限制,我们提出了一个新的标准:分布均一性指数(DHI)。DHI 已经在模拟图谱和制剂开发样品上进行了测试。由于正在研究不同的制剂,因此未使用经过验证的校准模型获得样品的分布图谱。获得的结果表明,含量均匀度值与分布图谱的 DHI 值之间存在线性关系。因此,即使在制剂开发过程中没有校准,DHI 方法似乎也是分析分布图谱均一性的合适工具。